Parathyroid hormone prodrug - Ascendis Pharma

Drug Profile

Parathyroid hormone prodrug - Ascendis Pharma

Alternative Names: ACP 014; TransCon parathyroid hormone; TransCon PTH

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascendis Pharma
  • Class
  • Mechanism of Action Parathyroid hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypoparathyroidism

Most Recent Events

  • 08 Jan 2018 Initial pharmacodynamics and pharmacokinetics data from a phase I trial in Hypoparathyroidism (In volunteers) released by Ascendis Pharma
  • 08 Jan 2018 Ascendis Pharma plans to advance TransCon PTH directly into phase III development in Hypoparathyroidism in the first quarter of 2019
  • 26 Sep 2017 Phase-I clinical trials in Hypoparathyroidism (In volunteers) in Australia (SC) (ACTRN12617001375347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top